Risk of first–time diagnosis of Alzheimer's disease in patients with type 2 diabetes (without obesity) (comparison between matched semaglutide vs other anti–diabetes medications groups)

Size/Group	Exposure Group	Comparison Group	Exposure Group Cases (Overall Risk)	Comparison Group Cases (Overall Risk)		HR (95% CI)
7,544	Semaglutide	Insulin	16 (0.21%)	44 (0.58%)		0.32 (0.18–0.57)
7,548	Semaglutide	Metformin	16 (0.21%)	38 (0.50%)		0.41 (0.23–0.73)
7,507	Semaglutide	DPP–4i	16 (0.21%)	32 (0.43%)		0.47 (0.26–0.86)
7,539	Semaglutide	SGLT2i	16 (0.21%)	29 (0.39%)		0.54 (0.29–0.99)
7,532	Semaglutide	SU	16 (0.21%)	43 (0.57%)		0.35 (0.20–0.62)
6,422	Semaglutide	TZD	15 (0.23%)	43 (0.67%)		0.33 (0.18–0.59)
7,539	Semaglutide	Other GLP–1RAs	16 (0.21%)	29 (0.39%)		0.54 (0.29–0.99)

Hazard Ratio (HR)

0.10 0.20 0.40 0.70 2.0 3.00 5.00 8.00